U.S. Markets open in 23 mins.

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
281.44-0.51 (-0.18%)
At close: 4:00PM EDT
People also watch
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets


    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.


    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • [!] Recently updated to now display all available spreads - Spread traders take a look at CreditSpreads.io, zero cost live feed of statistically profitable option credit spreads for the coming 4 weeks, sometimes including spreads for BIIB! High-probability option credit spreads provide you with a method to trade with defined risk and the maximum profit gained up front. CreditSpreads.io lazer-targets only the option spreads which fulfill its strict standards for probability and profit, and ensures sustained profitability by warning you of any approaching events which might affect the trade. www.creditspreads.io

    Sustainable, high probability, defined risk stock option trading opportunities.
  • I didn't see Renal Cell cancer research on BIIB pipeline? AVEO has Tivo for Renal Cell Ca, Recommended for Approval in the EU. Heading for $4. Once it's Approved...? $8+ Approval date getting close, end of Aug.
  • TSRO is weighing in.
  • any thoughts on SPINRAZA sales for Q2?
  • but🌱I🌱can🌱give🌱you🌱the🌱formula🌱for🌱failure-Which🌱is: http://dataunion.tistory.com/1313

    [2016-MAY] Biogen Idec Inc. NASDAQ : BIIB Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stock
  • Short interest increased slightly from 2,988,953 shares on 6/15/2017 to 3,109,113 shares on 6/30/2017.
    IMO just noise................
  • auph ready to break out
  • I hope nobody here got squeezed out when the stock sold off so badly. I really do think an announcement is coming and those in the know have been manipulating the stock price. glta
  • .....03:12 PM EDT, 06/21/2017 (MT Newswires) -- Shares of Biogen (BIIB) climbed more than 4% and peers also advanced intraday after a draft of an executive order on drug prices showed President Trump appears to give the pharmaceutical industry much of what it has asked for -- and no guarantee that costs to consumers will drop, according to a report from New York Times.
  • Every time I sell, then it goes up , what the hell
  • High volume today. Institutional buying!
  • go sidewey fer awhile? consolidate, and then anuther surge? jus wondering
  • Glad I sold Biib at $421/sh....I thugh this was overbought
  • This whole bio ride has been so hilarious... in March/April, the analysts were bashing every bio in sight and saying they were all #$%$ and the index fell from like 209 to 195. They kept bashing. Then the index broke support at 195 and went down to 189 for a day before bouncing back to 195... Ok, so now the index has run from 189 to 215 in short order. Keep in mind that it takes about $45M in total gains to go up 1 point, so we've gained about 1.1B in asset value. NOW the analysts are coming out of the wood work and upgrading all the bios left and right... Uh... you guys already missed the 26 point index run. I don't mind you guys helping push it higher, but just shows how useless analysts are.
  • Still saying the shake-up in BIIB management is not coincidental, new talent is coming in. I smell something is definitely in the making!
  • Is BIIB overvalued at current levels? I started receiving notifications from AWEsome_STOCK.S the other week and so far they have presented interesting new trade ideas.
  • down 2 percent over a bean counter.
  • BIIB just hired a new HR head: Biogen appoints Ginger Gregory executive vice president, chief human resources officer
    * Biogen Inc ( BIIB ) - Gregory, was most recently chief human resources officer at Shire Pharmaceuticals Source text for Eikon: Further company coverage
  • Thestreet article says the sell off was an overreaction and nothing points to internal issues. Obviously we aren't going up +8 tommorow, but feels like a one day event to me.